Adaptin Bio (APTN) Enterprise Value (2022 - 2026)

Adaptin Bio (APTN) has 5 years of Enterprise Value data on file, last reported at -$301309.0 in Q1 2026.

• For the quarter ending Q1 2026, Enterprise Value rose 87.31% year-over-year to -$301309.0; the trailing twelve-month figure through Mar 2026 stood at -$301309.0 (up 87.31% YoY), and the FY2025 full-year result was -$459174.0, down 1247.14% from the prior year.
• Enterprise Value rose to -$301309.0 in Q1 2026, from -$459174.0 in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$322.0 in Q3 2024 to a low of -$2.4 million in Q1 2025.
• A 5-year average of -$427849.7 and a median of -$28930.5 in 2024 frame the typical range for Enterprise Value.
• Across the five-year window, Enterprise Value tumbled 179741.3% in 2025 and jumped 87.31% in 2026, its largest moves.
• Tracing APTN's Enterprise Value over 5 years: stood at -$500.0 in 2022, then plunged by 850.8% to -$4754.0 in 2023, then sank by 616.98% to -$34085.0 in 2024, then slumped by 1247.14% to -$459174.0 in 2025, then surged by 34.38% to -$301309.0 in 2026.
• Business Quant data shows APTN's Enterprise Value at -$301309.0 in Q1 2026, -$459174.0 in Q4 2025, and -$579089.0 in Q3 2025.